Starpharma Holdings Secures $5.5 Million Upfront From Genentech for Oncology Drug Partnership

MT Newswires Live

Oct 22, 2025

Starpharma Holdings (ASX:SPL) secured a $5.5 million upfront payment from Genentech under a new licensing agreement to develop dendrimer-drug conjugates using its proprietary dendrimer-enhanced product (DEP) platform with Genentech's oncology medicines, according to a Wednesday Australian bourse filing.

The DEP technology enhances solubility, efficacy, pharmacokinetics, and safety across various drug types, including small molecules, peptides, proteins, chemotherapeutics, radiotheranostics, and antibody-drug conjugates, per the filing.

The company is also eligible to receive up to $564 million in development, commercial, and sales milestones, along with tiered royalties on worldwide sales, the filing added.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2577398073"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2577398073\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2577398073?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-22 12:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2577398073","market":"nz","top_or_hot":-1,"title":"Starpharma Holdings Secures $5.5 Million Upfront From Genentech for Oncology Drug Partnership","media":"MT Newswires Live","content":"<html><body><p> Starpharma Holdings (ASX:SPL) secured a $5.5 million upfront payment from Genentech under a new licensing agreement to develop dendrimer-drug conjugates using its proprietary dendrimer-enhanced product (DEP) platform with Genentech's oncology medicines, according to a Wednesday Australian bourse filing.</p><p>The DEP technology enhances solubility, efficacy, pharmacokinetics, and safety across various drug types, including small molecules, peptides, proteins, chemotherapeutics, radiotheranostics, and antibody-drug conjugates, per the filing.</p><p>The company is also eligible to receive up to $564 million in development, commercial, and sales milestones, along with tiered royalties on worldwide sales, the filing added.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Starpharma Holdings Secures $5.5 Million Upfront From Genentech for Oncology Drug Partnership</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStarpharma Holdings Secures $5.5 Million Upfront From Genentech for Oncology Drug Partnership\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-10-22 12:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Starpharma Holdings (ASX:SPL) secured a $5.5 million upfront payment from Genentech under a new licensing agreement to develop dendrimer-drug conjugates using its proprietary dendrimer-enhanced product (DEP) platform with Genentech's oncology medicines, according to a Wednesday Australian bourse filing.</p><p>The DEP technology enhances solubility, efficacy, pharmacokinetics, and safety across various drug types, including small molecules, peptides, proteins, chemotherapeutics, radiotheranostics, and antibody-drug conjugates, per the filing.</p><p>The company is also eligible to receive up to $564 million in development, commercial, and sales milestones, along with tiered royalties on worldwide sales, the filing added.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7508","symbol_name":"医药生物股","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2577398073","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2577398073","pubTimestamp":1761107008,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Starpharma Holdings  secured a $5.5 million upfront payment from Genentech under a new licensing agreement to develop dendrimer-drug conjugates using its proprietary dendrimer-enhanced product  platform with Genentech's oncology medicines, according to a Wednesday Australian bourse filing.The DEP technology enhances solubility, efficacy, pharmacokinetics, and safety across various drug types, including small molecules, peptides, proteins, chemotherapeutics, radiotheranostics, and antibody-drug conjugates, per the filing.The company is also eligible to receive up to $564 million in development, commercial, and sales milestones, along with tiered royalties on worldwide sales, the filing added.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7508":"医药生物股","BK7096":"制药","SPL.AU":"STARPHARMA HOLDINGS LTD","BK7501":"新冠治疗股"},"translate_title":"Starpharma Holdings从Genentech获得550万美元预付款用于肿瘤药物合作","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SPL.AU":1},"content_text":"Starpharma Holdings (ASX:SPL) secured a $5.5 million upfront payment from Genentech under a new licensing agreement to develop dendrimer-drug conjugates using its proprietary dendrimer-enhanced product (DEP) platform with Genentech's oncology medicines, according to a Wednesday Australian bourse filing.The DEP technology enhances solubility, efficacy, pharmacokinetics, and safety across various drug types, including small molecules, peptides, proteins, chemotherapeutics, radiotheranostics, and antibody-drug conjugates, per the filing.The company is also eligible to receive up to $564 million in development, commercial, and sales milestones, along with tiered royalties on worldwide sales, the filing added.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}